Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

FRIENDSWOOD, Texas–(BUSINESS WIRE)—- $CSTL #AJCC8–Castle announced a study showing DecisionDx-Melanoma provided significantly better risk stratification than AJCC8 staging in stage I melanoma.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks